The TGF-β-Th2 axis: A new target for cancer therapy?
The innate and adaptive immune responses are critical for the recognition and removal of pathogens. Moreover, in the last two decades, it has been demonstrated that immune cells are also key cells in the cancer-related immune response.1 Ideally, the immune system should eradicate the tumor cells to...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión enviada para evaluación y publicación |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/262354 |
| Acceso en línea: | http://hdl.handle.net/10261/262354 |
| Access Level: | acceso abierto |
| Palabra clave: | Type 2 immunity Cancer Hypoxia IL-4 TGF-β |
| Sumario: | The innate and adaptive immune responses are critical for the recognition and removal of pathogens. Moreover, in the last two decades, it has been demonstrated that immune cells are also key cells in the cancer-related immune response.1 Ideally, the immune system should eradicate the tumor cells to maintain homeostasis. However, it has been demonstrated that a dysregulation of the innate and adaptive immune responses could lead to tumorigenesis, inhibition of T- and B-cell activation, and stimulation of tumor proliferation and metastasis.2 The immune system can also promote tumor progression through a dynamic process called cancer immunoediting, by which cancer cells acquire mutations that allow them to evade the immune system. Tumor cells that undergo this process harbor a reduced immunogenicity and produce regulatory cytokines such as interleukin-10 (IL-10) and transforming growth factor β (TGF-β) that can inhibit T-cell functionality. |
|---|